Retatrutide
Retatrutide (development code LY3437943) is an investigational injectable peptide from Eli Lilly designed as a single-molecule agonist at three metabolic hormone receptors: GLP-1, GIP, and glucagon. It belongs to the emerging class of multi-receptor incretin agonists, an extension of the science behind approved GLP-1 and dual GLP-1/GIP medicines. Interest centers on its addition of glucagon-receptor activity, which is hypothesized to increase energy expenditure alongside appetite reduction. It is being studied primarily for obesity and related metabolic endpoints and is not approved by the FDA for any use.
Side effects & risks
The most commonly reported adverse effects in clinical trials are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reduced appetite, generally most pronounced during dose escalation and often lessening over time. Because of the glucagon-receptor component, increases in heart rate and the potential for effects on glucose regulation have been observed and are areas of active monitoring. As with other incretin-based agents, there are theoretical and class-level cautions regarding pancreatitis, gallbladder-related events, and, based on rodent studies of related drugs, thyroid C-cell tumors, so a personal or family history of medullary thyroid carcinoma or MEN2 is a recognized concern for this class. Rapid weight loss and reduced intake can carry risks of dehydration and nutritional inadequacy. The long-term safety profile is not established, and rare or delayed adverse effects may not yet be characterized. This compound is investigational, not approved for human use, and material sold for research is not verified for purity or safety. Anyone considering metabolic therapy should consult a qualified clinician rather than relying on research-use products.
Latest studies
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Chemists built and validated a single lab test that can identify and measure nine GLP-1 drugs at once, including semaglutide, tirzepatide, and retatrutide, in about 20 minutes. They confirmed it works on real marketed products, which matters for verifying what is actually in a vial.
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
Researchers compared semaglutide, tirzepatide and retatrutide head to head for effects on kidney scarring in mice with surgically obstructed ureters and in aged mice, plus human kidney cells. All three reduced fibrosis markers, but through partly different signalling pathways, and retatrutide had the largest effect at the doses tested. None of the animals were diabetic, which is the point: the effect did not appear to depend on glucose lowering.
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
A review of how GLP-1 drugs, tirzepatide, and triple agonists like retatrutide affect the cardiovascular system, arguing that less than a fifth of their cardiovascular benefit comes from blood-sugar control — the rest reflects weight, blood pressure, lipids, inflammation, and direct effects on heart muscle.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“5 weeks reta and forget”
A user marks five weeks into a retatrutide protocol, with the title's 'and forget' phrasing suggesting a low-maintenance routine or diminished appetite focus; a personal experience log rather than a data-driven discussion.
“Retatrutide mixture”
A user in a GLP-1 research community asks about a retatrutide mixture, most plausibly seeking guidance on reconstitution or combining it with another compound; no comments were pulled, so the thread reflects an open protocol question rather than reported outcomes.
“Am I doing it right?”
A retatrutide user asks the community to sanity-check their approach, a common pattern of newcomers seeking peer feedback on dosing or administration; with no comments pulled, the thread stands as an open protocol-verification question.
“Each 6days or 7days?”
A user asks whether retatrutide injections should be spaced every 6 or every 7 days, reflecting ongoing community debate about dosing frequency; reported protocols in this community typically use weekly intervals, and the thread is an open question with no comments pulled.
“5 months in!!”
A five-month progress update from a retatrutide user, apparently celebratory in tone; such milestone posts typically share weight change and protocol details, though with no comments pulled the specific numbers are not captured here.
Reported protocols (with caveats)
In the controlled trial setting, retatrutide has been administered as a once-weekly subcutaneous injection, using a gradual dose-escalation (titration) schedule that steps up over several weeks to improve tolerability, with studied maintenance doses reported in the single-digit to low-double-digit milligram-per-week range. In the research-chemical and community context, compounds sold as retatrutide are described as being used similarly, with slow titration from a low starting dose and weekly dosing, but reported protocols there are anecdotal and not standardized. Product sold under this name is offered strictly for research use only and is not manufactured, dosed, or quality-controlled for human consumption. There is no established, approved dosing regimen because the drug has not completed clinical development or received regulatory authorization. Any figures circulating in community discussions should be understood as reported research use, never as recommended dosing.